5-FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53-mutated colon cancer cells

Tomofumi Akasaka, Masahiko Tsujii, Jumpei Kondo, Yoshito Hayashi, Jin Ying, Yuquan Lu, Motohiko Kato, Takuya Yamada, Shunsuke Yamamoto, Takuya Inoue, Yoshiki Tsujii, Akira Maekawa, Tetsuji Fujinaga, Eri Shiraishi, Satoshi Hiyama, Takahiro Inoue, Shinichiro Shinzaki, Kenji Watabe, Tsutomu Nishida, Hideki IijimaTetsuo Takehara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The emergence of chemoresistance is a major limitation of current cancer therapies, and checkpoint kinase (Chk1) 1 positively correlates with resistance to chemo-.or radio-therapy. Cancer cells lacking p53 pathways are completely dependent on the S and G2/M checkpoints via Chk1; therefore, Chk1 inhibition enhances the cytotoxicity of DNA-damaging agents only in p53-deficient cells. However, little is known about the synergistic effect of Chk1 inhibition with 5-FU, the most frequently used antimetabolite, in chemoresistant colorectal cells. In this study, we found that 5-FU induced S-phase arrest only in p53-deficient colorectal cancer cells. 5-FU treatment induced DNA damage and activation of ataxia telangiectasia mutated (AT M) and Chk1, leading to S-phase arrest, and Chk1 inhibition using SB218078 reduced S-phase arrest and increased apoptosis in the presence of 5-FU. In contrast, in p53-deficient, 5-FU-resistant (5FUR) colon cancer cells that we developed, 5-FU enhanced DNA damage but did not induce Chk1/AT M activation or cell cycle arrest. SB218078 in combination with 5-FU did not induce apoptosis. These results indicate that 5-FU- resistance abrogated the anticancer effect amplified by Chk1 inhibition, even in p53-deficient cancer cells.

Original languageEnglish
Pages (from-to)63-70
Number of pages8
JournalInternational Journal of Oncology
Volume46
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

Fluorouracil
Colonic Neoplasms
S Phase
Ataxia Telangiectasia
DNA Damage
Apoptosis
Antimetabolites
Neoplasms
Checkpoint Kinase 1
Cell Cycle Checkpoints
Radio
Colorectal Neoplasms
DNA
Therapeutics

Keywords

  • 5-fluorouracil
  • Chk1
  • Colorectal cancer
  • P53

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

5-FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53-mutated colon cancer cells. / Akasaka, Tomofumi; Tsujii, Masahiko; Kondo, Jumpei; Hayashi, Yoshito; Ying, Jin; Lu, Yuquan; Kato, Motohiko; Yamada, Takuya; Yamamoto, Shunsuke; Inoue, Takuya; Tsujii, Yoshiki; Maekawa, Akira; Fujinaga, Tetsuji; Shiraishi, Eri; Hiyama, Satoshi; Inoue, Takahiro; Shinzaki, Shinichiro; Watabe, Kenji; Nishida, Tsutomu; Iijima, Hideki; Takehara, Tetsuo.

In: International Journal of Oncology, Vol. 46, No. 1, 01.01.2015, p. 63-70.

Research output: Contribution to journalArticle

Akasaka, T, Tsujii, M, Kondo, J, Hayashi, Y, Ying, J, Lu, Y, Kato, M, Yamada, T, Yamamoto, S, Inoue, T, Tsujii, Y, Maekawa, A, Fujinaga, T, Shiraishi, E, Hiyama, S, Inoue, T, Shinzaki, S, Watabe, K, Nishida, T, Iijima, H & Takehara, T 2015, '5-FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53-mutated colon cancer cells', International Journal of Oncology, vol. 46, no. 1, pp. 63-70. https://doi.org/10.3892/ijo.2014.2693
Akasaka, Tomofumi ; Tsujii, Masahiko ; Kondo, Jumpei ; Hayashi, Yoshito ; Ying, Jin ; Lu, Yuquan ; Kato, Motohiko ; Yamada, Takuya ; Yamamoto, Shunsuke ; Inoue, Takuya ; Tsujii, Yoshiki ; Maekawa, Akira ; Fujinaga, Tetsuji ; Shiraishi, Eri ; Hiyama, Satoshi ; Inoue, Takahiro ; Shinzaki, Shinichiro ; Watabe, Kenji ; Nishida, Tsutomu ; Iijima, Hideki ; Takehara, Tetsuo. / 5-FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53-mutated colon cancer cells. In: International Journal of Oncology. 2015 ; Vol. 46, No. 1. pp. 63-70.
@article{f3582e1cff894266a0ce8abef39696b5,
title = "5-FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53-mutated colon cancer cells",
abstract = "The emergence of chemoresistance is a major limitation of current cancer therapies, and checkpoint kinase (Chk1) 1 positively correlates with resistance to chemo-.or radio-therapy. Cancer cells lacking p53 pathways are completely dependent on the S and G2/M checkpoints via Chk1; therefore, Chk1 inhibition enhances the cytotoxicity of DNA-damaging agents only in p53-deficient cells. However, little is known about the synergistic effect of Chk1 inhibition with 5-FU, the most frequently used antimetabolite, in chemoresistant colorectal cells. In this study, we found that 5-FU induced S-phase arrest only in p53-deficient colorectal cancer cells. 5-FU treatment induced DNA damage and activation of ataxia telangiectasia mutated (AT M) and Chk1, leading to S-phase arrest, and Chk1 inhibition using SB218078 reduced S-phase arrest and increased apoptosis in the presence of 5-FU. In contrast, in p53-deficient, 5-FU-resistant (5FUR) colon cancer cells that we developed, 5-FU enhanced DNA damage but did not induce Chk1/AT M activation or cell cycle arrest. SB218078 in combination with 5-FU did not induce apoptosis. These results indicate that 5-FU- resistance abrogated the anticancer effect amplified by Chk1 inhibition, even in p53-deficient cancer cells.",
keywords = "5-fluorouracil, Chk1, Colorectal cancer, P53",
author = "Tomofumi Akasaka and Masahiko Tsujii and Jumpei Kondo and Yoshito Hayashi and Jin Ying and Yuquan Lu and Motohiko Kato and Takuya Yamada and Shunsuke Yamamoto and Takuya Inoue and Yoshiki Tsujii and Akira Maekawa and Tetsuji Fujinaga and Eri Shiraishi and Satoshi Hiyama and Takahiro Inoue and Shinichiro Shinzaki and Kenji Watabe and Tsutomu Nishida and Hideki Iijima and Tetsuo Takehara",
year = "2015",
month = "1",
day = "1",
doi = "10.3892/ijo.2014.2693",
language = "English",
volume = "46",
pages = "63--70",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - 5-FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53-mutated colon cancer cells

AU - Akasaka, Tomofumi

AU - Tsujii, Masahiko

AU - Kondo, Jumpei

AU - Hayashi, Yoshito

AU - Ying, Jin

AU - Lu, Yuquan

AU - Kato, Motohiko

AU - Yamada, Takuya

AU - Yamamoto, Shunsuke

AU - Inoue, Takuya

AU - Tsujii, Yoshiki

AU - Maekawa, Akira

AU - Fujinaga, Tetsuji

AU - Shiraishi, Eri

AU - Hiyama, Satoshi

AU - Inoue, Takahiro

AU - Shinzaki, Shinichiro

AU - Watabe, Kenji

AU - Nishida, Tsutomu

AU - Iijima, Hideki

AU - Takehara, Tetsuo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The emergence of chemoresistance is a major limitation of current cancer therapies, and checkpoint kinase (Chk1) 1 positively correlates with resistance to chemo-.or radio-therapy. Cancer cells lacking p53 pathways are completely dependent on the S and G2/M checkpoints via Chk1; therefore, Chk1 inhibition enhances the cytotoxicity of DNA-damaging agents only in p53-deficient cells. However, little is known about the synergistic effect of Chk1 inhibition with 5-FU, the most frequently used antimetabolite, in chemoresistant colorectal cells. In this study, we found that 5-FU induced S-phase arrest only in p53-deficient colorectal cancer cells. 5-FU treatment induced DNA damage and activation of ataxia telangiectasia mutated (AT M) and Chk1, leading to S-phase arrest, and Chk1 inhibition using SB218078 reduced S-phase arrest and increased apoptosis in the presence of 5-FU. In contrast, in p53-deficient, 5-FU-resistant (5FUR) colon cancer cells that we developed, 5-FU enhanced DNA damage but did not induce Chk1/AT M activation or cell cycle arrest. SB218078 in combination with 5-FU did not induce apoptosis. These results indicate that 5-FU- resistance abrogated the anticancer effect amplified by Chk1 inhibition, even in p53-deficient cancer cells.

AB - The emergence of chemoresistance is a major limitation of current cancer therapies, and checkpoint kinase (Chk1) 1 positively correlates with resistance to chemo-.or radio-therapy. Cancer cells lacking p53 pathways are completely dependent on the S and G2/M checkpoints via Chk1; therefore, Chk1 inhibition enhances the cytotoxicity of DNA-damaging agents only in p53-deficient cells. However, little is known about the synergistic effect of Chk1 inhibition with 5-FU, the most frequently used antimetabolite, in chemoresistant colorectal cells. In this study, we found that 5-FU induced S-phase arrest only in p53-deficient colorectal cancer cells. 5-FU treatment induced DNA damage and activation of ataxia telangiectasia mutated (AT M) and Chk1, leading to S-phase arrest, and Chk1 inhibition using SB218078 reduced S-phase arrest and increased apoptosis in the presence of 5-FU. In contrast, in p53-deficient, 5-FU-resistant (5FUR) colon cancer cells that we developed, 5-FU enhanced DNA damage but did not induce Chk1/AT M activation or cell cycle arrest. SB218078 in combination with 5-FU did not induce apoptosis. These results indicate that 5-FU- resistance abrogated the anticancer effect amplified by Chk1 inhibition, even in p53-deficient cancer cells.

KW - 5-fluorouracil

KW - Chk1

KW - Colorectal cancer

KW - P53

UR - http://www.scopus.com/inward/record.url?scp=84917711077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917711077&partnerID=8YFLogxK

U2 - 10.3892/ijo.2014.2693

DO - 10.3892/ijo.2014.2693

M3 - Article

C2 - 25310623

AN - SCOPUS:84917711077

VL - 46

SP - 63

EP - 70

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -